Latest Inflammation News

Microba Life Sciences reveals preliminary data from over 4,600 MetaXplore GI Plus tests showing significant clinical findings in the majority of patients, with two-thirds reporting symptom improvements following test-guided care.

Dimerix Limited has announced a US licensing transaction for its Phase 3 asset DMX-200 targeting FSGS, alongside progress updates on its clinical trial. The move underscores the company’s push to address a rare kidney disease with no approved therapies.

Mesoblast has commercially launched Ryoncil in the US for pediatric acute GVHD, backed by a strong cash position and advancing multiple cell therapy programs.

Syntara Limited reports significant clinical progress with its lead myelofibrosis drug SNT-5505 and launches a new trial for its next-generation anti-fibrotic skin treatment, supported by a solid $18 million cash reserve.

Noxopharm Limited has successfully cleared key preclinical hurdles for its SOF-SKN™ lupus drug and expanded its Sofra™ platform collaborations, supported by fresh funding to propel upcoming clinical trials.

Biome Australia has partnered with the Food and Beverage Accelerator (FaBA) to jointly develop its promising BMB18 probiotic strain, leveraging $50 million in Australian government funding while retaining full IP ownership.

Argenica Therapeutics reports compelling preclinical evidence that its lead candidate ARG-007 significantly reduces brain cell damage and inflammation in moderate traumatic brain injury models, marking a promising step toward new TBI treatments.

Argenica Therapeutics has reported compelling preclinical data showing ARG-007 significantly reduces brain cell damage and inflammation in moderate traumatic brain injury, matching levels seen in uninjured controls. This reinforces ARG-007’s potential as a breakthrough neuroprotective therapy.

Noxopharm has successfully completed key in vitro safety tests for its SOF-SKN™ lupus drug, paving the way for the upcoming HERACLES Phase 1 clinical trial.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.

Biome Australia Limited has announced encouraging results from functional studies on its probiotic strain BMB18, highlighting its potential to modulate immune responses, reduce inflammation, and support intestinal health. These findings pave the way for targeted clinical research and product innovation.

Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.